Ovarian Cancer Immunotherapy: Turning up the Heat

Eleonora Ghisoni, Martina Imbimbo, Stefan Zimmermann, Giorgio Valabrega

Research output: Contribution to journalReview article

Abstract

Epithelial ovarian cancer (EOC) is the leading cause of death among gynecological malignancies. Despite surgery and chemotherapy, 5-years survival rates have improved only modestly over the past few decades remaining at 45% for advanced stages. Therefore, novel therapies are urgently needed. The presence of tumor-infiltrating lymphocytes (TILs) in OC tumor microenvironment (TME) has already proved to be correlated with overall survival (OS), while immune evasion mechanisms are associated with poor prognosis. Although these data indicate that immunotherapy has a strong rationale in OC, single agent immune-checkpoints inhibitors (ICIs) have shown only modest results in this malignancy. In this review, we will discuss immune-targeting combination therapies and adoptive cell therapy (ACT), highlighting the challenges represented by these strategies, which aim at disrupting the stroma-tumor barrier to boost immune system against ovarian cancer.

Original languageEnglish
JournalInternational Journal of Molecular Sciences
Volume20
Issue number12
DOIs
Publication statusPublished - Jun 15 2019

    Fingerprint

Keywords

  • Animals
  • Antineoplastic Agents, Immunological/pharmacology
  • Biomarkers, Tumor
  • Clinical Trials as Topic
  • Combined Modality Therapy
  • Female
  • Humans
  • Immunotherapy/methods
  • Immunotherapy, Adoptive
  • Lymphocytes, Tumor-Infiltrating/drug effects
  • Molecular Targeted Therapy
  • Ovarian Neoplasms/immunology
  • T-Lymphocyte Subsets/drug effects
  • Tumor Microenvironment/drug effects

Cite this